# A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

> **NCT05627258** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 23 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB0115-00-AB

## Key facts

- **NCT ID:** NCT05627258
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-30
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627258, "A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05627258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*